These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 10566557

  • 1. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
    Loging WT, Reisman D.
    Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):1011-6. PubMed ID: 10566557
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
    Thomas S, Reisman D.
    Cancer Lett; 2006 Aug 18; 240(1):48-59. PubMed ID: 16236433
    [Abstract] [Full Text] [Related]

  • 5. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
    Kawamata H, Omotehara F, Nakashiro K, Uchida D, Shinagawa Y, Tachibana M, Imai Y, Fujimori T.
    Int J Oncol; 2007 May 18; 30(5):1089-97. PubMed ID: 17390010
    [Abstract] [Full Text] [Related]

  • 6. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A, Resnick MA.
    Oncogene; 2001 Jun 07; 20(26):3409-19. PubMed ID: 11423991
    [Abstract] [Full Text] [Related]

  • 7. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
    Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL, Koeffler HP.
    Oncogene; 1994 Jul 07; 9(7):1899-906. PubMed ID: 8208536
    [Abstract] [Full Text] [Related]

  • 8. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
    Willis A, Jung EJ, Wakefield T, Chen X.
    Oncogene; 2004 Mar 25; 23(13):2330-8. PubMed ID: 14743206
    [Abstract] [Full Text] [Related]

  • 9. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
    Mizuarai S, Yamanaka K, Kotani H.
    Cancer Res; 2006 Jun 15; 66(12):6319-26. PubMed ID: 16778209
    [Abstract] [Full Text] [Related]

  • 10. The properties of p53 proteins selected for the loss of suppression of transformation.
    Olson DC, Levine AJ.
    Cell Growth Differ; 1994 Jan 15; 5(1):61-71. PubMed ID: 8123594
    [Abstract] [Full Text] [Related]

  • 11. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.
    Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B, Levine AJ.
    Cell Growth Differ; 1990 Dec 15; 1(12):571-80. PubMed ID: 2288874
    [Abstract] [Full Text] [Related]

  • 12. Alterations in mitochondrial and apoptosis-regulating gene expression in photodynamic therapy-resistant variants of HT29 colon carcinoma cells.
    Shen XY, Zacal N, Singh G, Rainbow AJ.
    Photochem Photobiol; 2005 Dec 15; 81(2):306-13. PubMed ID: 15560738
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Differential gene expression in apoptosis: identification of ribosomal protein S29 as an apoptotic inducer.
    Khanna N, Reddy VG, Tuteja N, Singh N.
    Biochem Biophys Res Commun; 2000 Oct 22; 277(2):476-86. PubMed ID: 11032747
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study.
    Daoud SS, Munson PJ, Reinhold W, Young L, Prabhu VV, Yu Q, LaRose J, Kohn KW, Weinstein JN, Pommier Y.
    Cancer Res; 2003 Jun 01; 63(11):2782-93. PubMed ID: 12782583
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Inhibition mechanism of a newly cloned candidate tumor suppressor gene JST during hepatocarcinogenesis and its abnormal expression in human hepatocellular carcinoma from Qidong liver cancer risk area, China.
    Dong-Dong L, Xi-Ran Z.
    Hepatogastroenterology; 2004 Jun 01; 51(56):515-25. PubMed ID: 15086194
    [Abstract] [Full Text] [Related]

  • 20. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
    Chang FL, Ling YF, Lai MD.
    Anticancer Res; 2000 Jun 01; 20(1A):329-36. PubMed ID: 10769676
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.